Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2 ...
Opthea Limited to Present Sozinibercept Phase 2b Study Results at Macula Society 48th Annual Meeting
Opthea Limited announces presentation of sozinibercept data at the Macula Society Annual Meeting, showcasing superior outcomes in wet AMD treatment. Opthea Limited has announced that its novel therapy ...
Hosted on MSN
Opthea presents Wet AMD data at Macula Society Meet
Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the development of novel therapies to treat eye diseases, has shared new data ...
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) ...
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for ...
(MENAFN- GlobeNewsWire - Nasdaq) Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results